Adamas Pharmaceuticals (ADMS) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts ADMS Hot Sheet
Join SI Premium – FREE
Adamas Pharmaceuticals (NASDAQ: ADMS) reported Q2 EPS of ($0.78), $0.06 worse than the analyst estimate of ($0.72).
For earnings history and earnings-related data on Adamas Pharmaceuticals (ADMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
